Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4,4-Difluoro-Piperidinium SCHEMBL14655229 | 0.96 | HRH3 (0.37) | HRH3HPGDKMT2ASMN1; SMN2IRAK4 | |
| SCHEMBL2574751 | 0.88 | HTR6 (0.47) | HRH3HTR6 | |
| SCHEMBL15363252 | 0.88 | HTR6 (0.47) | HRH3HTR6 | |
| SCHEMBL2372681 | 0.88 | DPP4 (0.37) | HRH3IRAK4PLAT | |
| Hydrochloric Acid SCHEMBL23884910 | 0.86 | DPP4 (0.36) | HRH3HPGDKMT2ASMN1; SMN2IRAK4 | |
| Hydrochloric Acid SCHEMBL3606485 | 0.86 | DPP4 (0.36) | HRH3HPGDKMT2ASMN1; SMN2IRAK4 | |
| SCHEMBL27347572 | 0.83 | HTR6 (0.41) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| Hydrochloric Acid SCHEMBL27147799 | 0.81 | HPGD (0.43) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL1826521 | 0.79 | HRH3 (0.46) | HRH3HTR6 | |
| SCHEMBL13381568 | 0.78 | CYP2D6 (0.40) | HRH3HPGDKMT2ASMN1; SMN2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |
| CN-113939292-A | Inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2021066958-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | HRH3 1292/4885HPGD 4158/4885KMT2A 743/4885 |
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HRH3 400/4885HPGD 1059/4885KMT2A 2784/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HRH3 400/4885HPGD 1059/4885KMT2A 2784/4885 |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | HRH3 1163/4885HPGD 4153/4885KMT2A 740/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | HRH3 368/4885HPGD 990/4885KMT2A 3246/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | HRH3 1340/4885HPGD 4494/4885KMT2A 1575/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | HRH3 392/4885HPGD 1873/4885KMT2A 988/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | HRH3 1453/4885HPGD 3064/4885KMT2A 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.